Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Live SK08 Powder (Bacteroidetes Fragilis) in the Treatment of Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)

NCT06247046 is registered in ClinicalTrials.gov with Guangzhou Zhiyi Biotechnology Co., Ltd. as lead sponsor.

NCT NCT06247046
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06247046 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Live SK08 Powder (Bacteroidetes Fragilis) in the Treatment of Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Lead sponsor
Guangzhou Zhiyi Biotechnology Co., Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
March 16, 2024
Completion date
January 31, 2027
Enrollment
1,298 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

irritable bowel syndrome with diarrhea